AI and Rare Diseases ── 2026-11-14
New papers on rare diseases (other than neurological and cancer) and AI, collected from journal feeds, PubMed (searched across all journals) and OpenAlex (a public index used instead of Google Scholar), judged by Jev (an AI that makes language judgements): original research, AI central, which of 8 disease groups, treatment or trials, and then ranked by importance up to a daily limit. Journals are not filtered by impact factor; each paper shows its journal's IF-equivalent (OpenAlex two-year mean citedness) and the date of that value. Each entry shows the full original abstract.
Read by disease: Platforms(2) · Inborn errors of metabolism(0) · Genetic syndromes(0) · Rare blood disorders(1) · Immune and connective tissue(1) · Heart and lung(0) · Kidney, liver and gut(1) · Skin and bone(0)
Rare-disease diagnosis and drug discovery platforms and AI
- Abstract
BACKGROUND: In children, Kawasaki disease (KD) - characterized by immune dysregulation and vasculitis - represents the most common cause of acquired heart disease. Although cell adhesion molecules (CAMs) contribute significantly to the vascular inflammation observed in KD, how they act synergistically and how this knowledge might be applied clinically remain poorly understood. METHODS: Leveraging multiple public KD transcriptomic datasets, we identified differentially expressed CAM-related genes through differential expression analysis and WGCNA, then used four machine learning algorithms (Least Absolute Shrinkage and Selection Operator, eXtreme Gradient Boosting, random forest, and support vector machine recursive feature elimination) to build a six-gene diagnostic model. Immune infiltration was assessed via single sample Gene Set Enrichment Analysis, CIBERSORT, and MCP-Counter, and molecular subtyping with functional enrichment by clusterProfiler. RESULTS: This study pinpointed six core diagnostic genes. The model built from them showed excellent discriminative ability across training and several independent validation datasets. Immune profiling revealed a KD microenvironment skewed by overabundant innate immune cells (neutrophils, monocytes, macrophages) and marked deficiency of adaptive immune cells (CD8+ T cells, NK cells, B cells). Using these genes, patients split into two molecular subtypes, with subtype 2 featuring enhanced adaptive immune infiltration. CONCLUSION: A six-gene KD diagnostic model is proposed here, revealing immune imbalance, molecular subtypes, and potential drug targets, and offering novel insights into CAM-associated pathways.
Journal IF-equivalent: 2.5 (OpenAlex 2-year mean citedness, value as of 2026-11-12, retrieved 2026-11-13; not the official Clarivate IF)Reference: Shao Z, Ruan Z, Sheng F, Su C. Establishment and validation of a diagnostic model for Kawasaki disease based on cell adhesion molecule-related genes and analysis of immune-related features. Microvasc Res. 2026 Nov [Epub ahead of print]. doi:10.1016/j.mvr.2026.105036. PMID: 43014667.Checked: Abstract only - Abstract
BACKGROUND: Traditional molecular diagnosis of rare genetic diseases often struggles with complex genotype-phenotype relationships, such as pleiotropy and locus heterogeneity. Despite advances in next-generation sequencing, variant interpretation remains a major bottleneck, frequently requiring labor-intensive expert review to establish phenotypic specificity. To address this challenge, we developed GenPhenia, a deep learning-based framework designed to assist phenotype-driven gene prioritization using clinical features encoded with the Human Phenotype Ontology (HPO). RESULTS: GenPhenia leverages large-scale synthetic clinical history datasets and a graph neural network architecture with message-passing strategies combined with BERT-based phenotype embeddings to learn phenotype-gene associations. The model was validated using both ClinVar-derived datasets and real-world clinical cohorts. On the challenging MCRD benchmark dataset, GenPhenia achieved 60% Top-1 recall and 80% Top-10 recall, substantially outperforming previously reported methods, which achieved less than 30% Top-10 recall under the same conditions. Clinical case studies across endocrinology, cardiology, and immunology further demonstrate that the model effectively refines gene rankings as phenotypic specificity increases during the diagnostic process. CONCLUSIONS: GenPhenia provides a scalable and highly sensitive computational approach for phenotype-driven gene prioritization that aligns with the iterative nature of clinical phenotyping and genomic diagnosis. The framework may facilitate more efficient variant interpretation and support the integration of artificial intelligence methods into clinical genomics workflows for rare disease diagnosis.
Journal IF-equivalent: 4.6 (OpenAlex 2-year mean citedness, value as of 2026-11-12, retrieved 2026-11-13; not the official Clarivate IF)Reference: Brunello FG, Colangelo G, Rius A, Erra L, Lugones AC, Aguirre N, et al. GenPhenia: using deep neural networks to accelerate rare-disease diagnosis. Hum Genomics. 2026 Aug 14;20(1):159. doi:10.1186/s40246-026-01023-9. PMID: 43015840.Checked: Abstract only
Inborn errors of metabolism: treatment, trials and AI
No new qualifying paper for this issue.
Genetic syndromes and paediatric rare diseases: treatment, trials and AI
No new qualifying paper for this issue.
Rare blood disorders: treatment, trials and AI
- Abstract
Sickle cell disease (SCD) is a common inherited genetic disorder and contributor to global childhood mortality and morbidity, particularly in Sub-Saharan Africa. Craniofacial and skeletal changes have been described in SCD, but the subtle soft-tissue facial patterns and their variation have not been quantitatively characterized using machine-learning methods. We analyzed 308 front-facing smartphone photographs from 154 participants with electrophoresis-confirmed SCD and 154 age- and sex-matched controls aged from 5 months to 19 years recruited in Kinshasa, Democratic Republic of the Congo. Predefined geometric and texture-based facial descriptors were extracted from standardized images using manually annotated landmarks. An interpretable linear support vector machine with recursive feature elimination was evaluated using leave-one-out cross-validation, with features ranked according to their relevance for distinguishing participants with SCD from controls. Cross-sectional age- and sex- stratified analyses evaluated variation in selected features The facial analysis algorithm identified eight geometric and six texture discriminative features that were significantly different between the cohorts. A combination of six geometric features contributed most consistently to internal discrimination: distance between medial and lateral canthi, angle at nasal ala, distance from nasion to philtrum, distance from medial canthi to the columella, distance from columella to the lower lip, and distance between nasal alae. The model achieved an AUROC of 0.843 [95% CI: 0.798,0.887], and an accuracy of 0.795 [95% CI: 0.750,0.840]. Between-group difference was limited in the youngest age groups and were more pronounced in several older age groups. These findings demonstrate preliminary evidence that SCD is associated with quantifiable morphometric patterns. External, longitudinal, and clinically characterized studies are needed to determine whether these features may serve as reproducible digital biomarkers within a broader supportive disease-assessment framework.
Journal IF-equivalent: 8.7 (OpenAlex 2-year mean citedness, value as of 2026-11-12, retrieved 2026-11-14; not the official Clarivate IF)Reference: Spencer D, Liu X, Mosema-Be-Amoti K, Kandosi G, Bramble MS, Al Munajjed F, et al. Quantitative facial phenotyping and age-associated differences in Sickle cell disease using interpretable machine learning. PLOS Digit Health. 2026 Nov 12;5(11):e0001813. doi:10.1371/journal.pdig.0001813. PMID: 43019377.Checked: Abstract only
See all 1 Rare blood disorders papers →
Autoinflammatory, immunodeficiency and rare connective-tissue diseases: treatment, trials and AI
- Abstract
Lupus nephritis (LN) remains a major determinant of poor prognosis in systemic lupus erythematosus, yet reliable tools for early identification of unfavorable renal outcomes are lacking. This study aimed to identify early prognostic factors for complete renal response (CRR) at 12 months in active LN and to develop interpretable machine learning (ML) models for early prediction of treatment response. In this prospective cohort of 400 active LN patients followed for 12 months, the primary outcome was 12-month CRR. Candidate predictors were assessed at baseline and 3-month follow-up. Four ML models (Random Forest, Support Vector Machine, Elastic Net, and eXtreme Gradient Boosting) were developed and validated on a test set. Model performance was evaluated using area under the ROC curve (AUC), calibration and decision curve analyses, with feature importance assessed via SHapley Additive exPlanations (SHAP). 296 patients (74%) achieved CRR at 12 months. Baseline factors independently associated with CRR included 24-hour urinary total protein (24hUTP), higher serum albumin, shorter disease duration, and treatment-naïve status. Significant group differences emerged at 3 months across multiple parameters (all p < 0.05). Baseline‑only models showed limited discriminative ability (AUC ≤ 0.75), whereas incorporating 3-month data markedly improved performance; the Random Forest model achieved the best testing-set AUC (0.862, 95% CI: 0.775-0.949). SHAP analysis identified 3-month 24hUTP reduction as the most influential predictor of CRR. We developed an interpretable ML tool that accurately predicts 12-month CRR as early as 3 months post-treatment, highlighting the critical role of early proteinuria reduction as a key indicator for long-term renal outcomes.
Journal IF-equivalent: 5.1 (OpenAlex 2-year mean citedness, value as of 2026-11-12, retrieved 2026-11-13; not the official Clarivate IF)Reference: Song S, Fan Y, Zhang X, Cheng J, Gao D, Zhang J, et al. A machine learning-based predictive tool for complete renal response in lupus nephritis leverages the 3-month treatment milestone. Ren Fail. 2026 Nov 11;48(1):2751782. doi:10.1080/0886022x.2026.2751782. PMID: 43015004.Checked: Abstract only
See all 1 Immune and connective tissue papers →
Rare cardiovascular and respiratory diseases: treatment, trials and AI
No new qualifying paper for this issue.
Rare kidney, liver and gastrointestinal diseases: treatment, trials and AI
- Abstract
Objectives: Accurate quantification of total kidney volume (TKV) and Mayo imaging classification (MIC) is essential for assessing disease severity in autosomal dominant polycystic kidney disease (ADPKD). This study aimed to develop and validate a deep learning–based method using noncontrast computed tomography (CT) scans to automate TKV measurement and MIC assignment. Materials and methods A retrospective dataset of 60 ADPKD patients was used to train a three-dimensional (3D) UNet model for kidney segmentation and TKV estimation. Kidney axes were calculated using principal component analysis (PCA). The model was tested on consecutive scans from 30 patients (median interval: 3.6 years) and 28 external patient scans. Segmentation accuracy was evaluated using the Dice similarity coefficient (DSC), and measurement reliability was assessed using the intraclass correlation coefficient (ICC). MIC was assigned and compared across timepoints.
Results: The model achieved high segmentation accuracy (DSC: 0.93 ± 0.04 [mean ± standard deviation] and 0.94 ± 0.03 for consecutive scans; 0.96 ± 0.08 for external validation). Manual and automated TKV measurements were strongly correlated (ICC: 0.94–0.99, p < 0.001), with a mean volume error of 7.61 ± 7.26%. MIC assignment matched in 90–93.3% of cases. Kidney dimensions (length > 16.5 cm, width > 9.5 cm, depth > 8 cm) predicted high-risk MIC classes with positive predictive values > 88%. Longitudinal analysis showed significant increases in TKV and declines in estimated glomerular filtration rate–eGFR ( p < 0.001).
Conclusion: The proposed method enables accurate TKV quantification and MIC classification from noncontrast CT, supporting severity assessment and longitudinal monitoring in ADPKD. Key Points Question Can a deep learning method using noncontrast CT accurately automate total kidney volume measurement and Mayo Imaging Classification assignment in autosomal dominant polycystic kidney disease?
Findings: In internal and external testing, automated kidney segmentation showed high agreement with reference measurements and correctly assigned Mayo Imaging Classification in most cases with overall accuracy. Relevance statement Automated analysis of noncontrast CT provided reliable kidney volume quantification and disease severity classification, reducing manual workload while enabling longitudinal assessment of disease progression in autosomal dominant polycystic kidney disease.
Journal IF-equivalent: 6.5 (OpenAlex 2-year mean citedness, value as of 2026-11-12, retrieved 2026-11-14; not the official Clarivate IF)Reference: Koukoutegos K, Oyen T, Oyen R, De Keyzer F, Maes F, Bosmans H. Assessment of autosomal dominant polycystic kidney disease severity using deep learning–based kidney volumetry in CT. Eur Radiol Exp. 2026 Nov 12;10(1):176. doi:10.1186/s41747-026-00840-w. PMID: 43018898.Checked: Abstract only
See all 1 Kidney, liver and gut papers →
Rare skin and bone diseases: treatment, trials and AI
No new qualifying paper for this issue.